NCT03564613View on ClinicalTrials.gov

Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women

RecruitingOBSERVATIONAL

Enrollment

250

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions

HIV Infections

Interventions

DRUG

DTG

Subjects with DTG exposure during any trimester will be included

Trial Locations (1)

08041

RECRUITING

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

ViiV Healthcare

All Listed Sponsors

lead

ViiV Healthcare

INDUSTRY

NCT03564613 - Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women | Biotech Hunter | Biotech Hunter